U.S. Plans To Use Toyama’s Favipiravir In Ebola Fight
This article was originally published in PharmAsia News
Executive Summary
The U.S. is urgently trying to obtain approval for the influenza drug favipiravir (T-705), developed by Fujifilm Holdings subsidiary Toyama Chemicals, for the treatment of Ebola hemorrhagic fever currently raging in West Africa.